Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Information

The following table is representative of revenue and significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment (in thousands).


		Years Ended December 31,
		2025				2024
Revenues		$	1,123			$	43
Program expenses (1)
Clinical trial studies			3,016				2,800
Manufacturing, RenovoCath			793				418
Other research and development expenses			396				161
Non-program expenses (2)			4,660				3,556
Personnel compensation and related expenses, including share-based compensation			4,768				4,078
Other segment items (3)			(1,342	)			(2,156	)
Net loss		$	11,168			$	8,814

(1) Includes external research expenses, clinical studies, manufacturing development and non-recurring engineering costs, professional and consulting, regulatory, and trade shows.

(2) Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, and other office expenses.

(3) Includes Interest income and interest expense and gain recognized on the fair value of common stock warrant liability.